These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32276934)

  • 1. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
    Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
    Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
    Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
    Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
    Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker H; Romeo C; Ray-Coquard I
    Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 12. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    Luo L; Keyomarsi K
    Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
    Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
    J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.